1. Introduction {#sec1-ijerph-16-03644}
===============

Tobacco use imposes a very large public health burden worldwide \[[@B1-ijerph-16-03644]\]. In the European Union, it is the largest avoidable health risk and the most significant cause of premature death, accounting for over 300,000 deaths per year \[[@B2-ijerph-16-03644]\]. On average, around half of smokers die 14 years earlier than non-smokers. Smoking is a major risk factor for at least two of the leading causes of mortality, cardiovascular diseases and cancer, and an important risk factor for many serious respiratory diseases \[[@B2-ijerph-16-03644]\].

However, patterns differ greatly depending on gender and age. According to World Bank data, between 2005 and 2016, smoking prevalence decreased by 32% for males, whereas for females it decreased by 11% \[[@B3-ijerph-16-03644]\]. According to the National Alcohol and Drugs Survey in Spain \[[@B4-ijerph-16-03644]\], in 2017 the highest prevalence for the previous 10 years was registered among men aged 15--34. In contrast, for women in this age group, the prevalence was the second lowest in the series. For individuals aged 35 to 64, the prevalence among men was the highest recorded since 2003, when 43.7% of men in this age group smoked tobacco daily. Regardless of sex and age, the survey showed an increase in the prevalence of daily tobacco use in 2017 compared with 2015. This increase is especially noticeable among men (increase of 4 points). Meanwhile, daily tobacco use among women aged 35 to 64 has shown a steady upward trend since 2013, reaching its highest point in the historical series in 2017 (30.5%). The percentage of women aged 35 to 64 who smoke daily exceeded the figure registered in the youngest group (15--34 years). Furthermore, a white paper addressing smoking from a gender perspective in Spain \[[@B5-ijerph-16-03644]\] had already stated that the epidemic patterns among men and women were different and that the burden of smoking-related diseases was more evident among men because women began to smoke several decades later. However, this situation is now changing and the differences need to be thoroughly studied.

Economic data and methods play an important role in tobacco control research, from estimating the costs of tobacco-related diseases and mortality to evaluating the cost-effectiveness of tobacco control interventions, programmes and policies. Some studies have quantified the economic cost that smoking imposes on society \[[@B6-ijerph-16-03644],[@B7-ijerph-16-03644],[@B8-ijerph-16-03644],[@B9-ijerph-16-03644],[@B10-ijerph-16-03644],[@B11-ijerph-16-03644]\]. In fact, some of these papers have measured the economic impact of smoking reduction \[[@B11-ijerph-16-03644],[@B12-ijerph-16-03644]\], or productivity losses caused by smoking \[[@B7-ijerph-16-03644],[@B8-ijerph-16-03644],[@B9-ijerph-16-03644],[@B13-ijerph-16-03644]\] or both at the same time \[[@B6-ijerph-16-03644],[@B10-ijerph-16-03644],[@B14-ijerph-16-03644]\]. All papers concluded that investment in tobacco cessation interventions have led to reductions in smoking prevalence, savings in both healthcare and productivity costs as well as reductions in a high number of related diseases in the population. Thus, the amounts reported as saved by smoking reduction interventions account for billions of EUR or \$US across countries.

Healthcare costs associated with diseases are a relevant indicator for measuring the impact of the tobacco epidemic. However, these costs are neither the only nor the most significant category of costs \[[@B7-ijerph-16-03644],[@B8-ijerph-16-03644],[@B9-ijerph-16-03644],[@B13-ijerph-16-03644]\]. A report on damage caused by smoking in the EU27 found that the monetised cost of premature mortality, at standard value of statistical life (VSL) prices, amounted to 4.40% of total gross domestic product in the region. In fact, this was by far the largest component of the overall costs of smoking \[[@B15-ijerph-16-03644]\]. An alternative to the VSL approach to reveal the economic impact of smoking is the estimation of social costs associated with tobacco use \[[@B10-ijerph-16-03644],[@B13-ijerph-16-03644]\]. One of their components is the output loss associated with dying prematurely \[[@B12-ijerph-16-03644]\]. While foregone economic output is only one of the dimensions of loss due to early death, it is by no means a negligible one. Indeed, lost economic output constitutes a considerable part of the economic burden of smoking, but many studies do not include it because there is no available information \[[@B16-ijerph-16-03644]\].

Smoking is also recognised as an important problem by the political establishment. Spain has been very active in the implementation of policies on tobacco use in public places. The Economic and Social Council of Spain, in its opinion on Act No. 28/2005, warned that public expenditure on tobacco-related costs was higher than tobacco excise duties \[[@B17-ijerph-16-03644]\]. In consequence, several laws and regulations have been passed over the last 10 years, most remarkably a total smoking ban in public places in 2010, with the aim of increasing the life expectancy and improving the quality of life of the non-smoking population. There are limited studies on morbidity and mortality and healthcare costs associated with smoking in Spain, although the scientific community acknowledge that it is the public health problem that causes the highest avoidable social costs \[[@B8-ijerph-16-03644],[@B9-ijerph-16-03644]\]. However, these studies have concentrated mainly on calculating healthcare cost and on excess sick leave among smokers, but less on estimating economic losses associated with premature deaths related to tobacco use. Moreover, most studies have calculated the economic costs from a sample of workers, not at national level, and have not considered the possibility of age and gender differences.

Smoking, as a severe socioeconomic problem, not only results in an increase in healthcare costs, but also in costs due to productivity losses. There have been some studies that have calculated the number of deaths, years of potential life lost and productivity losses for the United States \[[@B18-ijerph-16-03644]\] and for Germany \[[@B12-ijerph-16-03644]\]. However, to our knowledge, there are no studies assessing the cost of foregone economic output due to premature mortality from smoking in the Spanish population and accounting for gender and age differences. The aim of this paper was to estimate the value of foregone economic output, number of deaths and potential years of working life lost attributable to premature deaths caused by tobacco use for the Spanish population, considering the evolution of tobacco use by gender. In order to achieve this objective, a microsimulation model of labour income, supported by the theoretical approach of human capital models \[[@B19-ijerph-16-03644]\], was developed. More precisely, the average earnings of a worker were used as a proxy for estimating labour productivity losses associated with leaving the labour market prematurely as a result of a health problem or a premature death. The hypothesis for testing this model was whether gender differences exist for the outcome measures calculated.

First, a section on methods details the human capital approach, data used and the simulation model built to calculate the main three outcome measures: number of premature deaths, years of potential productive life lost (YPPLL) and the loss of productivity attributable to tobacco use. The results section gives details on the results for each of these outcome measures. The discussion section compares the results obtained in this paper with other similar works already published. Lastly, a conclusions section provides a summary of the results obtained and suggestions for future research on this topic.

2. Materials and Methods {#sec2-ijerph-16-03644}
========================

2.1. Materials {#sec2dot1-ijerph-16-03644}
--------------

Based on the availability of data in the various databases used in this analysis, the analysis has been performed for 2002, 2006, 2010 and 2016. This period was also chosen in order to include some years before and after the last economic crisis in Spain dated around 2008 and to include normative changes related to tobacco consumption. All calculations have been carried out for the total population and according to gender in order to test the hypothesis for gender differences across the outcome measure to be calculated.

For this purpose, we used data from the structural wage survey in Spain for 2002, 2006, 2010 and 2016 \[[@B20-ijerph-16-03644]\]. The concept of salary earnings includes both cash and in-kind payments made to workers for time worked or work done, along with payment for periods of time not worked, such as holidays and public holidays. This gross salary includes the pay-as-you-go social security contributions made by employers on behalf of the worker and withheld income tax. Furthermore, future flow of production lost was adjusted by employment rate (according to gender, age and year). These employment data were obtained from the Labour Force Survey of the National Statistics Institute (INE), where the employment rate is defined as the percentage of the employed population in relation to the working-age population \[[@B21-ijerph-16-03644]\]. The employed population were individuals of working age who had worked for at least one hour during the reference week in exchange for remuneration (salary, wage, business benefit, etc.) in cash or in kind. Individuals who have jobs but have been temporarily absent due to illness, holidays, etc. are also considered part of the employed population. The employment rate was adjusted by sex and age for each year considered. Data on mortality were obtained from the INE's death statistics according to cause of death. Other data necessary for the calculation of this measure---i.e., number of deaths---were obtained from global burden of disease reports for 2005 to 2014. This source provides annual information on deaths by cause (International Classification of Diseases of the World Health Organization-10th revision) \[[@B22-ijerph-16-03644]\]. The diseases included in the analyses comprised malignant neoplasms, cardiovascular diseases and respiratory diseases, according to the evidence available \[[@B23-ijerph-16-03644],[@B24-ijerph-16-03644]\]. [Appendix A](#app1-ijerph-16-03644){ref-type="app"}, [Table A1](#ijerph-16-03644-t0A1){ref-type="table"}, details the ICD-10 codes for the various diseases included \[[@B22-ijerph-16-03644]\].

2.2. Method {#sec2dot2-ijerph-16-03644}
-----------

The human capital (HC) approach is employed for estimating labour losses. This is the method most commonly used in the vast majority of studies on the economic cost of smoking \[[@B11-ijerph-16-03644]\]. HC theory considers that the average wage obtained by the worker is a reasonable measure of (or the monetary value of) labour productivity \[[@B19-ijerph-16-03644]\]. Therefore, this method considers that the withdrawal of an individual's labour due to premature death or permanent disability results in a loss to society of that individual's future production. It is standard practice to estimate gross earnings, which includes payroll taxes and other employer-paid benefits---i.e., the full cost of employee compensation \[[@B25-ijerph-16-03644]\]. The theoretical justification for using total employer compensation per worker as a proxy for individual productivity is marginal productivity theory, according to which employers equate the marginal cost of employee time with the expected marginal contribution to output \[[@B25-ijerph-16-03644],[@B26-ijerph-16-03644]\]. Additionally, although, ideally, such losses would be adjusted by as many variables as possible (e.g., sex, age, level of education, region, labour category, etc.), we were only able to obtain the cause of death by sex and age, as it was the case in the majority of studies applying this theory \[[@B27-ijerph-16-03644],[@B28-ijerph-16-03644]\]. Therefore, labour productivity was approximated through remuneration in the labour market, using deaths and the employment rate for each year, by sex and age.

Taking into account the theory of human capital approach, a simulation model was constructed, once the age of death of each individual and the expected salaries were known, in order to calculate the present and future rate of production loss due to a premature death caused by tobacco. Firstly, years of potential life lost (YPLL) were estimated. Then, the number of deaths in each age group was multiplied by the average of the remaining life expectancy for each age group. Thus, the number of YPLL of the premature deaths of n individuals was calculated as follows:$$YPLL^{j} = \sum_{i = 1}^{n}d_{i}^{j} \ast L_{i}^{j}$$ where *j* is the gender, *d* is the deaths at the mid-point of each age group; and *L* is the average of remaining life expectancy for that age group.

Secondly, YPPLL were calculated. All deaths before 65 years of age (the legal age of retirement) were considered. Then, YPPLL was calculated by multiplying the number of deaths for a given age group by the expected remaining productive life years (until retirement age) for each age group. The number of YPPLL was calculated as follows:$$YPPLL^{j} = \sum_{i = 1}^{n}d_{i}^{j} \ast {(Wu - Wl)}_{i}^{j}$$ where *d* is the deaths at the mid-point of each age group; *Wu* is the upper limit of working age (65 years) and *Wl* is the age of death.

Finally, the calculated YPPLL was multiplied by sex and age-specific wages, adjusting by employment rate, between age of death and retirement age. Labour productivity losses (LP) can thus be estimated as follows:$$LP^{j} = \sum_{i = 1}^{n}YPPLL_{i}^{j} \ast S_{i}^{j} \ast e_{i}^{j}$$ where *S* is the wage adjusted by age and gender; and *e* is the employment rate adjusted by age and gender.

In order to conduct this analysis, the sample size was defined as the total number of deaths in the working age population by sex and cause of death for Spain, obtained from the National Statistics Institute \[[@B29-ijerph-16-03644]\]. To estimate premature deaths and YPPLL associated with tobacco consumption, we applied the attributable fraction (AF) method. The AF is the difference between overall average risk of the entire population (both exposed and unexposed) and average risk in the unexposed population, expressed as a fraction of the overall average risk. One of the most frequent interpretations of the AF is the proportion of disease risk or incidence (premature deaths in our study) that could be eliminated from the population if exposure (smoking) was eliminated. Attributable fractions were obtained from the Spanish Ministry of Health \[[@B30-ijerph-16-03644]\]. Total deaths for each underlying disease by sex and age were calculated. Deaths, YPPLL and labour productivity losses associated with tobacco use were only estimated in people over 35 years of age, as the AF was also only available for that age onward.

Therefore, for practical purposes, our analysis focused on labour productivity losses due to premature deaths attributable to tobacco use in the Spanish population aged 35 to 64 (the legal age of voluntary retirement is 65 years), by gender, in 2002, 2006, 2010 and 2016. In addition, 35 is the age threshold from which the effects of smoking on health was reflected in the data \[[@B30-ijerph-16-03644]\]. For that reason, our analysis focused on the population aged from 35 to 64.

For the baseline case, an annual discount rate of 3% and an annual labour productivity growth rate of 1% was applied to future income values obtained. A univariate deterministic sensitivity analysis was performed on two alternative discount rates (0% and 6%), as recommended in the Spanish Guidelines for Economic Evaluation \[[@B31-ijerph-16-03644],[@B32-ijerph-16-03644]\] and two new labour productivity growth rates (0% and 2%). Finally, an additional sensitivity analysis was carried in order to isolate the epidemiological effect of the economic cycle so that we could test whether the labour productivity losses associated with tobacco use would be different if economic instability had not existed over the period considered. For this purpose, we re-estimated the losses with the average employment rate for the entire period instead of applying the employment rate for each year. Monetary values were converted to constant 2016 euros (base year) applying the GDP deflator.

3. Results {#sec3-ijerph-16-03644}
==========

This section presents the estimations for number of premature deaths, YPPLL, and loss of productivity attributable to tobacco for the Spanish population over 35 years of age (), by gender, for the years 2002--2006--2010--2016. Some indicators to contextualize tobacco use in Spain are shown in [Appendix A](#app1-ijerph-16-03644){ref-type="app"}, [Table A2](#ijerph-16-03644-t0A2){ref-type="table"}.

3.1. Deaths in the Working Age Population {#sec3dot1-ijerph-16-03644}
-----------------------------------------

[Table 1](#ijerph-16-03644-t001){ref-type="table"} shows the resulting estimations for the number of deaths associated with tobacco use in the working age population. In terms of weight, malignant neoplasms of the trachea, bronchus and lung are responsible for around 62% of all premature deaths in 2016, with respiratory diseases accounting for the smallest share of this estimation.

In terms of the evolution during the period considered, tobacco-related deaths from malignant neoplasms and respiratory diseases have increased by 14% and 8%, between 2002 and 2016, respectively, while deaths caused by cardiovascular diseases have decreased by 11%. Overall, the number of deaths attributable to tobacco increased by 4.6% between 2002 and 2016. However, for males the number of deaths decreased by 8.5% whereas for females, deaths increased by around 99%---i.e., they virtually doubled. Hence, there are gender differences in the number of deaths, and therefore the hypothesis established is confirmed. The explanation may lie in the increase in the number of cases of the diseases included in the model for women over the years and, as noted above, in the increase in smoking prevalence among women aged 35--64. The increase in deaths among women is mainly explained by an increase in the number of cancer deaths, which rose by 1326 from 2002 to 2016.

3.2. YPPLLs {#sec3dot2-ijerph-16-03644}
-----------

[Table 2](#ijerph-16-03644-t002){ref-type="table"} shows results in YPPLLs for the total population and by gender. In terms of weight, malignant neoplasms of the trachea, bronchus and lung are responsible for around 36% of all YPPLLs, with respiratory diseases accounting for the smallest share. Overall, the number of YPPLLs attributable to tobacco fell by 12.3% between 2002 and 2016. This reduction is mainly explained by the reduction in cardiovascular diseases, which accounted for almost 11,400 fewer YPPLLs. However, the trend by gender is markedly different. For males, the YPPLLs have decreased by 22%, while for females it has increased by 41.9%. Hence, there are gender differences in the number of YPPLLs, and the hypothesis established is therefore also confirmed for this outcome measure.

A comparison with the previous table reveals a downward trend in YPPLLs, while the trend of premature deaths has remained stable or increased slightly on average for males, but not for females, among whom YPPLLs have increased by almost 50%. This trend is explained by the fact that the average age of premature deaths in the working age population rose during the period. For instance, for the two main causes of death associated with smoking, lung cancer and acute myocardial infarction (AMI), the average age of death among men of working age increased from 55.5 years in 2002 to 57.4 years in 2016. Among women, the age rose from 51.4 to 55.9 years. In the case of the AMI, the average age of death went from 53.4 years in 2002 to 54.7 years in 2016 for men of working age and from 51.4 years to 54.0 years for women of working age. Hence, we are not seeing a decline in premature mortality; deaths are simply occurring at a later age.

3.3. Labour Losses {#sec3dot3-ijerph-16-03644}
------------------

[Table 3](#ijerph-16-03644-t003){ref-type="table"} shows the monetary values of estimated labour losses in constant 2016 euros. Annex B shows the same results but in nominal prices. The total labour productivity losses associated with tobacco amount to €2268.8 million, €1900.3 million, €1600.0 million and €1540.68 million for 2002, 2006, 2010 and 2016, respectively. Malignant neoplasms are the group of diseases that account for the highest proportion of labour loss associated with tobacco use, as they represent almost 55% of the total loss. Cardiovascular diseases (especially myocardial infarction and other ischaemic disease) are second, followed by respiratory diseases, accounting for 39% and 7% of the total productivity loss, respectively.

In general, the results indicate that labour losses associated with tobacco use have decreased from €2269 million to €1541 million during the period analysed, a reduction of 32%. Cardiovascular diseases account for the highest reduction in losses, as losses due to these diseases have decreased by €323 million, equivalent to more than 36%. Losses associated with cancers have also decreased by 30% over the last 14 years, dropping from €1229 million to €858 million.

Again, the results clearly differ by gender. Although the total reduction of labour losses is 32%, the decrease for males was almost 40%, but for females, the labour losses rose by more than 100% during the period. Nevertheless, total losses among men are still much higher than among women. The favourable trend in the case of men and the unfavourable trend in the case of women, however, makes the relative weight shift from 94.5% vs. 5.5% in 2002 to 83.8% vs. 16.2% in 2016. There are also gender differences for labour losses, and therefore the hypothesis established is also confirmed for this outcome measure.

[Appendix A](#app1-ijerph-16-03644){ref-type="app"}, [Table A3](#ijerph-16-03644-t0A3){ref-type="table"}, [Table A4](#ijerph-16-03644-t0A4){ref-type="table"} and [Table A5](#ijerph-16-03644-t0A5){ref-type="table"} show the results in current values for each year, without applying the deflator (A3 for the base case and both, A4 and A5, for the sensitivity analysis). [Table A6](#ijerph-16-03644-t0A6){ref-type="table"} and [Table A7](#ijerph-16-03644-t0A7){ref-type="table"} in the supplementary material show the results obtained from the sensitivity analysis, applying an annual discount rate of 6% and an annual labour productivity growth rate of 0% ([Table A6](#ijerph-16-03644-t0A6){ref-type="table"}), and an annual discount rate of 0% and annual labour productivity growth rate of 2% ([Table A7](#ijerph-16-03644-t0A7){ref-type="table"}). Both tables confirm the gender differences encountered so far.

[Table A8](#ijerph-16-03644-t0A8){ref-type="table"}, in the appendix, shows the results from the analysis isolating the epidemiological effect of the economic cycle, applying the average employment rate for the entire period. from the results, it is clear that, in general, if the economic cycle is isolated, for 2002 the labour productivity losses would be €2,245.66 million, 1% lower in comparison with the estimates for the base case for that year. Likewise, for 2016, the labour losses would be 0.04% lower if the economic cycle is isolated, while for 2006 and 2010 the losses would be slightly higher than in those years without isolating the economic situation (5% and 4%, for 2006 and 2010, respectively).

4. Discussion {#sec4-ijerph-16-03644}
=============

This work covers a gap in information in Spain concerning the economic impact of smoking by gender, beyond its healthcare costs. The revelation of social costs associated with smoking does not replace epidemiological, clinical and healthcare cost information. On the contrary, it complements it and sheds light on an unknown dimension (hidden social costs) that enables a deeper understanding of the effects of smoking. This information may be a useful tool for public decision-makers in the planning of their preventive strategies and policies, and it might also be incorporated into economic evaluations of treatments to encourage smoking cessation.

This study confirms the hypothesis of gender differences in number of deaths, YYPLL and labour losses, as did previously published literature for Germany \[[@B14-ijerph-16-03644]\]. Other studies have calculated these outcome measures for the United States \[[@B18-ijerph-16-03644]\]; however, gender differences were not highlighted and evaluated specifically, as we did in this study. The two previous studies were published more than a decade ago, so new evidence, such as that produced in this paper, was needed. Other literature on economic costs and productivity losses have been found in the literature, but none of those studies calculated the impact of labour losses, using deaths averted and YPPLLs \[[@B6-ijerph-16-03644],[@B7-ijerph-16-03644],[@B8-ijerph-16-03644],[@B9-ijerph-16-03644],[@B10-ijerph-16-03644],[@B11-ijerph-16-03644],[@B12-ijerph-16-03644],[@B13-ijerph-16-03644],[@B14-ijerph-16-03644]\]. Our results show that men continue to account for the greatest burden of premature deaths, YPPLLs and labour losses associated with smoking. However, the trend observed among men is favourable, whereas the opposite is true of women. This inverse effect is in line with the prevalence trends for the two genders. As previously noted, the prevalence of smoking among women aged 35 to 64 years increased by almost 5% from 2002 to 2016, whereas for men in the same age group it decreased by 2%.

There are two additional factors that help to explain our results. The first is an increase in the average age of death among people of working age. The second factor is not so positive and shows a different trend for men and women over the period: the weight of female deaths within total smoking-related deaths in the working age population increased. The explanation may lie in the increase in the number of cases of the diseases included in the model for women over the years and, as noted above, in the increase in smoking prevalence among women aged 35--64. For example, in the case of lung cancer, the percentage of female deaths out of total deaths in 2002 was 10.4%. In 2016, it was 26.5%. In the case of the AMI, the proportion rose from 10.3% in 2002 to 14.2% in 2016. This increase in the proportion of female deaths reduces labour losses, since the employment rate and wages are lower in the case of women. The favourable trend in estimated labour losses is thus due to a positive factor (increase in the age of death) and to another factor related to the functioning of the Spanish labour market. Care should therefore be taken in interpreting the results.

The overall evolution of labour losses shows a clear downward trend, owing to the favourable trend for men, but not for women. Nevertheless, even though labour losses are declining, they still have a very significant impact from an economic point of view. The weight of labour productivity losses caused by premature deaths attributable to tobacco represented 0.24% of GDP in 2002, 0.18% in 2006, 0.15% in 2010 and 0.14% in 2016. Regarding total health spending (public and private), the weight of labour productivity losses caused by premature deaths attributable to tobacco is comparable to 2.2% of total health expenditure in 2006, 1.6% in 2010 and 1.5% in 2016 (data on total health spending not available for 2002).

Although we do not have information on labour losses caused by temporary or permanent absence due to illness, using the data on distribution of labour productivity losses estimated by Peña-Longobardo et al. (2016) \[[@B33-ijerph-16-03644]\] for major groups of diseases for Spain in 2009, a preliminary extrapolation of the impact of smoking on the loss of labour productivity can be made. The estimate indicates productivity losses (premature mortality, temporary and permanent absence due to illness) on the order of €4436.6 million in 2002, €4339.6 million in 2006, €3825.6 million in 2010 and €3834.5 million in 2016 (nominal values). This would mean figures equivalent to 0.59%, 0.43%, 0.35% and 0.34% of Spanish GDP in the years 2002, 2006, 2010 and 2016, respectively, and 5.35%, 3.82% and 3.77% of total health expenditure for the years 2006, 2010 and 2016, respectively.

Broadly, although the figures estimated showed that smoking can have hideous consequences for the economic situation of a country, few national studies have focused on the economic impact of smoking. Other economic analysis carried out in Spain recommended increasing the market price of cigarettes, as the price is much lower than the mortality cost per pack of cigarettes. More precisely, this study showed that the private mortality cost of smoking is €78 per pack of cigarettes for men and €54 per pack for women, with a statistical life value among Spanish smokers of €3.78 million \[[@B34-ijerph-16-03644]\]. For this reason, any interventions or programmes focused on reducing tobacco use should be considered in decision-making. Hormigo et al. analysed the efficiency (in terms of both costs and benefits) of a school-based smoking prevention program in Barcelona, considering as benefits both healthcare costs and avoided productivity losses (with a focus on higher productivity and years of working life gained). The healthcare benefits per averted smoker were €1997.57, but the indirect benefits per averted smoker were €23,258, of which 91% was due to avoided productivity losses (€21,260 per person). The authors concluded that the benefits of school-based tobacco prevention programmes, in terms of healthcare costs and productivity losses avoided, are far greater than the costs and therefore recommended that such programmes should be implemented \[[@B35-ijerph-16-03644]\].

Some limitations of this study should be noted. The AF for mortality was used as a proxy for smoking-attributable healthcare utilisation and expenditure, as no relative risk estimates for morbidity were available. Clearly, this assumption might lead to an overestimation or underestimation for morbidity AFs, depending on the disease. However, the estimate used for AF has been published by the Ministry of Health of Spain and should be based on good quality evidence and therefore be a good proxy for calculating national impacts \[[@B30-ijerph-16-03644]\]. The number of deaths was obtained from the Spanish National Institute of Statistics. There are other international public sources providing the number of deaths that could have facilitated future comparisons of the results with the results of other countries, such as the global burden of disease estimates. Different sources of information could lead to different results estimations. The authors of this paper believed that the national estimates were more reliable for making national estimations, but probably if future comparisons need to be made with other countries, other international data sources would be recommendable. Additional evidence on other smoking-related diseases could emerge, and other estimates would therefore need to be calculated to account for the new evidence. Age differences were also detected by this study, but for practical reasons-showing the results disaggregated by age would result in an unmanageable number of tables-we have not included the results in this paper. Indeed, differences observed across age ranges would not imply different policy decisions or actions.

5. Conclusions {#sec5-ijerph-16-03644}
==============

As the average age of death caused by tobacco use is low (working age), smoking has a significant economic impact for society as a whole in terms of labour losses. However, this impact differs by gender (strongly concentrated in men, but the trend observed for men is favourable, whereas the opposite is identified for women). Although the anti-smoking laws previously approved \[[@B17-ijerph-16-03644]\] have helped to decrease the prevalence of male smokers, this has not occurred in the case of females, leading to a considerable increase in productivity losses associated with premature deaths. These results are aligned with previously published work for Germany \[[@B12-ijerph-16-03644]\]. These findings would imply that careful attention needs to be payed to reinforcing smoking cessation interventions among women in order to mitigate the effect that smoking seems to have had in recent years in this subgroup of the population. Primary healthcare centres should probably pay special attention to strengthening the brief advice intervention for smoking cessation in the female population. Stronger intervention measures against smoking should be taken without delay to reduce the health impact of smoking, especially in the female population. The findings of this study may help to create evidence to highlight the economic problems associated with smoking in Spain. This could encourage further stricter public policies, such as stiffer tax policy. Additionally, the results from this paper could be used in the future to study whether future public investment in smoking cessation policies will be offset by the savings produced in terms of the economic impact of tobacco on society.

Several future lines of research should be considered. Firstly, it might be advisable to extrapolate this analysis to other European countries in order to better calculate the societal costs of smoking in Europe and contribute to better estimations of the efficiency of smoking cessation interventions. In order to calculate these productivity losses and incorporate them in an economic evaluation, it is important to consider differences in impact by gender. It is not expected that these estimates will change recommendations in terms of the efficiency of the smoking cessation interventions, but they could reveal the hidden cost of smoking and potential social savings derived from primary prevention of smoking. And secondary, prevention of diseases associated with this behaviour could also help to reinforce health policy decisions to invest in public health interventions across European countries. Spain is a country where the economic impact of smoking has scarcely been quantified. Therefore, further research on economic impact, including healthcare costs and informal care costs, should be undertaken in order to complement this information. Gender differences in these different types of costs should also be explored.

Any future strategies or programmes should take into account the productivity losses associated with premature deaths (with special emphasis on female deaths) due to smoking, so that any health policy decisions can lead to an efficient allocation of resources, considering a wider perspective of the consequences of tobacco use.
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Smoking-related diseases considered in the analysis.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  General Category                Specific Category (I)                                                                                                                                             Specific Category (II)                                         Disease Code\
                                                                                                                                                                                                                                                                   (ICD-10)
  ------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------- ---------------
  Tumours                         Lung cancer                                                                                                                                                       Lung cancer                                                    C33--C34

  Other cancers                   Lip, pharynx and oral cavity, oesophagus, stomach, pancreas, larynx, cervix, kidney and renal pelvis, bladder, liver, colon and rectum, acute myeloid leukaemia   C00--C14\                                                      
                                                                                                                                                                                                    C15\                                                           
                                                                                                                                                                                                    C16\                                                           
                                                                                                                                                                                                    C18\                                                           
                                                                                                                                                                                                    C19\                                                           
                                                                                                                                                                                                    C20\                                                           
                                                                                                                                                                                                    C22\                                                           
                                                                                                                                                                                                    C25\                                                           
                                                                                                                                                                                                    C32\                                                           
                                                                                                                                                                                                    C53\                                                           
                                                                                                                                                                                                    C64\                                                           
                                                                                                                                                                                                    C65\                                                           
                                                                                                                                                                                                    C67\                                                           
                                                                                                                                                                                                    C92                                                            

  Cardiovascular diseases         Ischaemic heart disease                                                                                                                                           MI+ and other ischaemic diseases                               I20--I25

  Other heart diseases            Rheumatic heart disease, cardiopulmonary diseases and other forms of heart disease                                                                                I00--I09\                                                      
                                                                                                                                                                                                    I26--I51                                                       

  Stroke                                                                                                                                                                                            I60--I69                                                       

  Other cardiovascular diseases   Atherosclerosis, aortic aneurysm, other arterial diseases and diabetes mellitus                                                                                   I70--I78                                                       

  Respiratory diseases            Chronic obstructive pulmonary disease                                                                                                                             Bronchitis, emphysema and chronic obstruction of the airways   J40--J44

  Other respiratory diseases      Pneumonia and influenza and tuberculosis                                                                                                                          J09--J18\                                                      
                                                                                                                                                                                                    A15--A19                                                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Source: WHO, 2004.
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###### 

General description of some indicators.

  Disease                                                                         2002          2006     2010     2016
  ------------------------------------------------------------------------------- ------------- -------- -------- --------
  Employment rate (35--64 years)                                                  79.6%         81.1%    72,0%    72.9%
  Average wages (euros per year)                                                  22,335        22,720   25,479   25,924
  Proportion of smokers in total population over 16 years of age ^a^              37.48%        35.27%   33.82%   28.24%
  Proportion of premature deaths out of total premature deaths (all causes) ^a^   25.85%        24.79%   25.77%   26.73%
                                                                                  **Females**                     
  Employment rate (35--64 years)                                                  43.4%         52.1%    54.5%    59.4%
  Average wages (euros per year)                                                  15,848        16,499   19,735   20,131
  Proportion of smokers in total population over 16 years of age ^b^              24.62%        23.85%   23.45    20.80%
  Proportion of premature deaths above total premature deaths (all causes)        8.85%         9.26%    12.89%   16.47%

^a^ These data are aligned with the estimates of the Spanish Ministry of Health \[Ministerio de Sanidad, Servicios Sociales e Igualdad. Muertes atribuibles al consumo de tabaco Tobacco en España, 2000-2014. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad, 2016\]. This report estimated that in that five-year period, deaths attributable to tobacco accounted for 25% of total deaths among persons aged 35 to 64 years and 12% among persons aged 65 and over. ^b^ Due to lack of information for some years, data are for 2003, 2006, 2009 and 2017.
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###### 

Labour losses (base case) (millions of euros).

  Disease                                                                                                           2002      2006      2010      2016
  ----------------------------------------------------------------------------------------------------------------- --------- --------- --------- ---------
  Cancer                                                                                                            975.75    972.26    909.70    858.24
  Malignant neoplasms of the trachea, bronchus and lung                                                             659.02    669.47    627.65    577.68
  ther neoplasms (\*)                                                                                               316.72    302.79    282.06    280.56
  Cardiovascular diseases                                                                                           706.83    696.26    576.67    567.35
  Ischaemic heart disease (MI+ other ischaemic diseases)                                                            410.76    405.96    328.31    304.93
  Other heart diseases                                                                                              137.69    137.89    131.67    143.81
  Stroke                                                                                                            105.08    102.30    78.78     76.30
  Other cardiovascular diseases (atherosclerosis, aortic aneurysm, other arterial diseases and diabetes mellitus)   53.30     50.11     37.91     42.31
  Respiratory diseases                                                                                              118.23    105.73    96.73     114.99
  Chronic obstructive pulmonary disease (bronchitis, emphysema and chronic obstruction of the airways)              55.21     45.68     44.89     47.57
  Other respiratory diseases (pneumonia and influenza and tuberculosis)                                             63.02     60.05     51.84     67.42
  Total                                                                                                             1800.81   1774.25   1583.10   1540.58

Source: own calculations.
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###### 

Labour losses (discount rate 6%; annual production rate 0%) (millions of euros).

  Disease                                                                                                           2002      2006      2010      2016
  ----------------------------------------------------------------------------------------------------------------- --------- --------- --------- ---------
  Cancer                                                                                                            79,769    79,584    75,507    72,048
  Malignant neoplasms of the trachea, bronchus and lung                                                             53,968    54,819    52,227    48,712
  Other neoplasms (\*)                                                                                              25,801    24,765    23,280    23,336
  Cardiovascular diseases                                                                                           56,523    55,837    46,362    46,027
  Ischaemic heart disease (MI+ and other ischaemic diseases)                                                        32,834    32,486    26,396    24,756
  Other heart diseases                                                                                              10,893    11,011    10,452    11,531
  Stroke                                                                                                            8450      8212      6380      6232
  Other cardiovascular diseases (atherosclerosis, aortic aneurysm, other arterial diseases and diabetes mellitus)   4347      4129      3134      3508
  Respiratory diseases                                                                                              9712      8705      8000      9595
  Chronic obstructive pulmonary disease (bronchitis, emphysema and chronic obstruction of the airways)              4757      3926      3848      4115
  Other respiratory diseases (pneumonia and influenza and tuberculosis)                                             4955      4780      4152      5480
  Total                                                                                                             146,004   144,127   129,868   127,670

Source: own calculations.
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###### 

Labour losses (discount rate 0%; annual production rate 2%) (millions of euros).

  Disease                                                                                                           2002      2006      2010      2016
  ----------------------------------------------------------------------------------------------------------------- --------- --------- --------- ---------
  Cancer                                                                                                            124,761   124,108   113,817   106,029
  Malignant neoplasms of the trachea, bronchus and lung                                                             84,077    85,406    78,258    70,931
  Other neoplasms (\*)                                                                                              40,683    38,702    35,559    35,098
  Cardiovascular diseases                                                                                           93,224    91,323    75,222    73,243
  Ischemic heart disease (MI+ and other ischaemic diseases)                                                         54,046    53,342    42,766    39,271
  Other heart diseases                                                                                              18,386    18,201    17,488    18,873
  Stroke                                                                                                            13,941    13,422    10,185    9775
  Other cardiovascular diseases (atherosclerosis, aortic aneurysm, other arterial diseases and diabetes mellitus)   6851      6358      4784      5324
  Respiratory diseases                                                                                              151.04    134.58    122.00    143.61
  Chronic obstructive pulmonary disease (bronchitis, emphysema and chronic obstruction of the airways)              65.99     54.88     54.01     56.60
  Other respiratory diseases (pneumonia and influenza and tuberculosis)                                             85.05     79.71     67.99     87.01
  Total                                                                                                             1924.05   1901.88   1656.80   1585.35

Source: own calculations.
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###### 

Sensitivity analysis l. Labour losses (constant 2016 euros) (millions of euros). Annual discount rate 6%. Annual labour productivity growth rate 0%.

  Diseases                                                                                                          2002   2006    2010   2016                                                           
  ----------------------------------------------------------------------------------------------------------------- ------ ------- ------ ------ ------- ------ ------ ------- ------- -------- -------- --------
  Cancer                                                                                                            1005   955     50     853    799     54     763    660     103     720      588      132
  Malignant neoplasms of the trachea, bronchus and lung                                                             680    644     36     587    550     37     528    450     78      487      390      97
  Other neoplasms(\*)                                                                                               325    310     15     265    249     16     235    210     25      234      199      35
  Cardiovascular diseases                                                                                           712    671     41     598    555     43     468    420     48      460      405      55
  Ischaemic heart disease (MI+ and other ischaemic diseases)                                                        413    396     17     348    330     18     267    247     20      247      224      23
  Other heart diseases                                                                                              137    128     9      118    108     10     106    93      13      116      100      16
  Stroke                                                                                                            106    95      11     88     77      11     64     52      12      62       51       11
  Other cardiovascular diseases (atherosclerosis, aortic aneurysm, other arterial diseases and diabetes mellitus)   54     51      3      44     41      3      31     28      3       35       31       4
  Respiratory diseases                                                                                              122    115     7      94     86      8      81     70      11      96       77       19
  Chronic obstructive pulmonary disease (bronchitis, emphysema and chronic obstruction of the airways)              60     58      2      42     40      2      39     35      4       41       34       7
  Other respiratory diseases (pneumonia and influenza and tuberculosis)                                             63     58      5      52     46      6      42     35      7       55       43       12
  Total                                                                                                             1839   1740    99     1544   1440    104    1313   1,150   163     1277     1071     206
  \% of labour losses by gender out of total                                                                        100%   94.6%   5.4%   100%   93.3%   6.7%   100%   87.6%   12.4%   100%     83.9%    16.1%
  Variation in labour losses 2002--2016                                                                             \-     \-      \-     \-     \-      \-     \-     \-      \-      −30.6%   −38.4%   108.1%

Source: own calculations. (\*) Lip, pharynx and oral cavity, esophagus, stomach, pancreas, larynx, cervix, kidney and renal pelvis, bladder, liver, colon and rectum, acute myeloid leukaemia.
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###### 

Sensitivity Analysis II. Labour losses (constant 2016 euros) (millions of euros). Annual discount rate 0%. Annual labour productivity growth rate 2%.

  Diseases                                                                                                          2002   2006    2010   2016                                                        
  ----------------------------------------------------------------------------------------------------------------- ------ ------- ------ ------ ------- ------ ------ ------- ------ ------ -------- -------
  Cancer                                                                                                            1572   1488    84     1329   1241    88     1150   988     162    1060   860      200
  Malignant neoplasms of the trachea, bronchus and lung                                                             1059   999     60     915    853     62     791    668     123    709    562      147
  Other neoplasms(\*)                                                                                               513    489     24     414    388     26     359    320     39     351    298      53
  Cardiovascular diseases                                                                                           1174   1104    70     978    906     72     761    682     79     733    644      89
  Ischaemic heart disease (MI+ and other ischaemic diseases)                                                        681    652     29     571    541     30     432    400     32     393    355      38
  Other heart diseases                                                                                              232    216     16     195    178     17     176    155     21     189    163      26
  Stroke                                                                                                            175    156     19     144    125     19     103    83      20     97     79       18
  Other cardiovascular diseases (atherosclerosis, aortic aneurysm, other arterial diseases and diabetes mellitus)   87     81      6      68     63      5      48     43      5      53     46       7
  Respiratory diseases                                                                                              190    178     12     145    132     13     124    106     18     143    114      29
  Chronic obstructive pulmonary disease (bronchitis, emphysema and chronic obstruction of the airways)              83     79      4      59     56      3      54     48      6      57     47       10
  Other respiratory diseases (Pneumonia and influenza and tuberculosis)                                             107    99      8      85     76      9      69     58      11     86     67       19
  Total                                                                                                             2935   2770    165    2452   2280    172    2034   1775    259    1936   1618     318
  \% of labour losses by gender out of total                                                                        100%   94.4%   5.6%   100%   93.0%   7.0%   100%   87.3%   1.7%   100%   83.6%    16.4%
  Variation in labour losses 2002--2016                                                                             \-     \-      \-     \-     \-      \-     \-     \-      \-     −34%   −41.6%   92.7%

Source: own calculations. (\*) Lip, pharynx and oral cavity, esophagus, stomach, pancreas, larynx, cervix, kidney and renal pelvis, bladder, liver, colon and rectum, acute myeloid leukaemia.
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###### 

Sensitivity Analysis III. Labour losses (constant 2016 euros) (millions of euros).

  Diseases                                                                                                          2002      2006      2010      2016
  ----------------------------------------------------------------------------------------------------------------- --------- --------- --------- ---------
  Cancer                                                                                                            1216.29   988.64    955.67    852.99
  Malignant neoplasms of the trachea, bronchus and lung                                                             822.31    680.61    658.45    571.57
  Other neoplasms (\*)                                                                                              393.97    308.03    297.21    281.42
  Cardiovascular                                                                                                    881.67    709.02    607.08    574.14
  Ischaemic heart disease (MI+ and other ischaemic diseases)                                                        510.06    412.58    346.37    310.22
  Other heart diseases                                                                                              172.14    140.64    138.48    145.16
  Stroke                                                                                                            132.82    104.82    82.23     76.11
  Other cardiovascular diseases (atherosclerosis, aortic aneurysm, other arterial diseases and diabetes mellitus)   66.66     50.98     40.00     42.65
  Respiratory diseases                                                                                              147.71    107.64    101.78    114.10
  Chronic obstructive pulmonary disease (bronchitis, emphysema and chronic obstruction of the airways)              68.85     46.22     47.46     47.26
  Other respiratory diseases (pneumonia and influenza and tuberculosis)                                             78.86     61.42     54.32     66.84
  Total                                                                                                             2245.66   1805.30   1664.53   1541.23

Source: own calculations. (\*) Lip, pharynx and oral cavity, esophagus, stomach, pancreas, larynx, cervix, kidney and renal pelvis, bladder, liver, colon and rectum, acute myeloid leukaemia.
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###### 

Deaths in working age population (35 to 64 years).

  Disease                                                                                                           2002     2006     2010    2016                                                                  
  ----------------------------------------------------------------------------------------------------------------- -------- -------- ------- -------- -------- ------- -------- -------- ------- -------- -------- -------
  Cancer                                                                                                            7437     6592     845     7427     6491     935     8471     6817     1654    8483     6312     2171
  Malignant neoplasms of trachea, bronchus and lung                                                                 5074     4511     563     5068     4480     588     5495     4768     1177    5894     4331     1563
  Other neoplasms (\*)                                                                                              2364     2081     282     2358     2011     347     2526     2049     477     2589     1981     609
  Cardiovascular diseases                                                                                           4670     4056     614     4697     4023     674     4100     3460     639     4151     3451     700
  Ischaemic heart disease (MI+ and other ischaemic diseases)                                                        2593     2323     270     2572     2269     303     2198     1924     274     2146     1842     304
  Other heart diseases                                                                                              882      740      141     936      783      153     917      752      165     1006     816      189
  Stroke                                                                                                            770      619      151     763      600      163     623      473      150     615      471      144
  Other cardiovascular diseases (atherosclerosis, aortic aneurysm, other arterial diseases and diabetes mellitus)   426      375      51      426      371      55      362      312      50      384      322      62
  Respiratory diseases                                                                                              1064     929      135     965      815      150     953      772      181     1147     844      303
  Chronic obstructive pulmonary disease (bronchitis, emphysema and chronic obstruction of the airways)              630      581      49      527      476      50      569      486      83      598      449      149
  Other respiratory diseases (pneumonia and influenza and tuberculosis)                                             433      348      85      438      339      99      384      286      98      549      395      154
  Total                                                                                                             13,171   11,578   1593    13,088   11,319   1759    13,524   11,050   2474    13,781   10,607   3174
  \% of deaths by gender out of total                                                                               100%     87.9%    12.1%   100%     86.5%    13.4%   100%     81.7%    18.3%   100%     77%      23%
  Variation in number of premature deaths 2002--2016                                                                \-       \-       \-      \-       \-       \-      \-       \-       \-      4.6%     −8.4%    99.2%

Source: own calculations. MI: Myocardial infarction. (\*) Lip, pharynx and oral cavity, esophagus, stomach, pancreas, larynx, cervix, kidney and renal pelvis, bladder, liver, colon and rectum, acute myeloid leukemia.
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###### 

Years of potential productive life lost (YPPLL) in working age population (35 to 64 years).

  Disease                                                                                                           2002      2006      2010     2016                                                                         
  ----------------------------------------------------------------------------------------------------------------- --------- --------- -------- --------- --------- -------- --------- --------- -------- --------- -------- --------
  Cancer                                                                                                            74,568    63,738    10,830   73,203    61,883    11,320   74,990    57,756    17,234   69,128    49,773   19,356
  Malignant neoplasms of trachea, bronchus and lung                                                                 50,623    42,982    7641     50,272    42,517    7755     52,265    39,453    12,812   47,245    33,049   14,196
  Other neoplasms (\*)                                                                                              23,945    20,756    3189     22,931    19,366    3565     22,725    18,304    4422     21,883    16,724   5159
  Cardiovascular diseases                                                                                           53,181    44,627    8555     51,628    42,853    8775     43,924    36,181    7744     41,786    34,172   7614
  Ischaemic heart disease (MI+ and other ischaemic diseases)                                                        29,802    26,217    3585     29,013    25,271    3742     24,136    20,960    3176     21,899    18,683   3217
  Other heart diseases                                                                                              10,525    8542      1983     10,470    8401      2069     10,166    8101      2066     10,692    8509     2183
  Stroke                                                                                                            8641      6357      2283     8266      5970      2296     6528      4559      1969     5981      4383     1598
  Other cardiovascular diseases (atherosclerosis, aortic aneurysm, other arterial diseases and diabetes mellitus)   4213      3510      703      3880      3211      669      3094      2560      534      3214      2597     617
  Respiratory diseases                                                                                              9354      7831      1523     8294      6657      1637     7969      6130      1839     9279      6573     2706
  Chronic obstructive pulmonary disease (bronchitis, emphysema and chronic obstruction of the airways)              4351      3847      505      3541      3092      449      3829      3070      759      3838      2834     1004
  Other respiratory diseases (pneumonia and influenza and tuberculosis)                                             5003      3984      1019     4754      3565      1188     4140      3060      1080     5441      3739     1702
  Total                                                                                                             137,103   116,195   20,908   133,125   111,393   21,733   126,883   100,067   26,817   120,193   90,518   29,676
  \% of YPPLL by gender out of total                                                                                100%      84.8%     15.2%    100%      83.7%     16.3%    100%      78.9%     21.1%    100%      75.3%    24.7%
  Variation in the number of YPPLL 2002--2016                                                                       \-        \-        \-       \-        \-        \-       \-        \-        \-       −12.3%    −22.1%   41.9%

Source: own calculations. MI: Myocardial infarction. (\*) Lip, pharynx and oral cavity, oesophagus, stomach, pancreas, larynx, cervix, kidney and renal pelvis, bladder, liver, colon and rectum, acute myeloid leukaemia.
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###### 

Labour losses (constant millions of 2016 euros) in working age population (35 to 64 years).

  Disease                                                                                                           2002   2006    2010   2016                                                           
  ----------------------------------------------------------------------------------------------------------------- ------ ------- ------ ------ ------- ------ ------ ------- ------- -------- -------- --------
  Cancer                                                                                                            1229   1166    63     1042   975     67     920    793     127     858      699      159
  Malignant neoplasms of the trachea, bronchus and lung                                                             830    785     45     717    670     47     634    538     96      577      460      117
  Other neoplasms (\*)                                                                                              399    381     18     324    304     20     285    254     31      281      239      42
  Cardiovascular diseases                                                                                           891    839     52     745    691     54     583    523     60      567      499      68
  Ischaemic heart disease (MI+ and other ischaemic diseases)                                                        518    496     22     435    412     23     331    307     24      305      276      29
  Other heart diseases                                                                                              174    162     12     148    135     13     133    117     16      143      124      19
  Stroke                                                                                                            132    118     14     109    95      14     79     64      15      76       62       14
  Other cardiovascular diseases (atherosclerosis, aortic aneurysm, other arterial diseases and diabetes mellitus)   67     63      4      54     50      4      38     34      4       43       37       6
  Respiratory diseases                                                                                              149    140     9      113    104     9      97     84      13      115      92       23
  Chronic obstructive pulmonary disease (bronchitis, emphysema and chronic obstruction of the airways)              70     67      3      49     47      2      45     40      5       47       39       8
  Other respiratory diseases (pneumonia and influenza and tuberculosis)                                             79     73      6      64     57      7      52     44      8       54       53       1
  Total                                                                                                             2269   2144    124    1901   1770    131    1600   1399    201     1541     1291     25
  \% of labour losses by gender out of total                                                                        100%   94.5%   5.5%   100%   93.1%   6.9%   100%   87.5%   12.5%   100%     83.8%    16.2%
  Variation in labour losses 2002--2016                                                                             \-     \-      \-     \-     \-      \-     \-     \-      \-      −32.1%   −39.8%   101.6%

Source: own calculations. MI: Myocardial Infarction. (\*) Lip, pharynx and oral cavity, oesophagus, stomach, pancreas, larynx, cervix, kidney and renal pelvis, bladder, liver, colon and rectum, acute myeloid leukaemia.
